


Healthcare News Roundup: Oncology
HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
HSMN NewsFeed - 8 May 2017
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
HSMN NewsFeed - 8 May 2017
New Varian Cancer Treatment Platform Draws Large Crowds at ESTRO 36 Tradeshow
New Varian Cancer Treatment Platform Draws Large Crowds at ESTRO 36 Tradeshow
HSMN NewsFeed - 3 May 2017
GammaDelta Therapeutics Expands Management Team Led by Paolo Paoletti as CEO
GammaDelta Therapeutics Expands Management Team Led by Paolo Paoletti as CEO
HSMN NewsFeed - 1 May 2017
Leading Protein Scientist Dr. Asya Grinberg Joins Dragonfly Therapeutics as Head of Biologics
Leading Protein Scientist Dr. Asya Grinberg Joins Dragonfly Therapeutics as Head of Biologics
HSMN NewsFeed - 28 Apr 2017
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
HSMN NewsFeed - 27 Apr 2017
Rigel Announces Tavalisse(TM) as Proprietary Name for Fostamatinib in the United States
Rigel Announces Tavalisse(TM) as Proprietary Name for Fostamatinib in the United States
HSMN NewsFeed - 25 Apr 2017
FDA Takes Action Against 14 Companies for Selling Illegal Cancer Treatments
FDA Takes Action Against 14 Companies for Selling Illegal Cancer Treatments
HSMN NewsFeed - 24 Apr 2017
Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer
Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer
HSMN NewsFeed - 24 Apr 2017
Seno Medical Instruments Appoints Ann Waterhouse as VP, Quality Assurance and Regulatory Affairs
Seno Medical Instruments Appoints Ann Waterhouse as VP, Quality Assurance and Regulatory Affairs
HSMN NewsFeed - 19 Apr 2017
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
HSMN NewsFeed - 17 Apr 2017
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
HSMN NewsFeed - 12 Apr 2017
Roche Launches Antibody Test to Aid in Diagnosis of Challenging Prostate Cancer Cases
Roche Launches Antibody Test to Aid in Diagnosis of Challenging Prostate Cancer Cases
HSMN NewsFeed - 4 Apr 2017
NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership
NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership
HSMN NewsFeed - 3 Apr 2017
MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer
MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer
HSMN NewsFeed - 3 Apr 2017
BioCryst Announces Mundipharma Receives Approval for Mundesine(R) in Japan
BioCryst Announces Mundipharma Receives Approval for Mundesine(R) in Japan
HSMN NewsFeed - 30 Mar 2017
Third Rock Ventures Launches Tango Therapeutics with $55 Million Series A Investment
Third Rock Ventures Launches Tango Therapeutics with $55 Million Series A Investment
HSMN NewsFeed - 29 Mar 2017
Tyme Technologies Announces Two New Board of Director Appointments -- David Carberry and James Biehl
Tyme Technologies Announces Two New Board of Director Appointments -- David Carberry and James Biehl
HSMN NewsFeed - 27 Mar 2017
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
HSMN NewsFeed - 22 Mar 2017
Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia
Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia
HSMN NewsFeed - 21 Mar 2017
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
